Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03291041 · ClinicalTrials.gov registry record · Phase 2
A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag Disorder
A Phase 2 study of Jet Lag Disorder, sponsored by Vanda Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 3
- Study locations
NCT03291041: Completed Phase 2 study of Jet Lag Disorder, sponsored by Vanda Pharmaceuticals.
NCT03291041 is a Phase 2 study of Jet Lag Disorder that has completed, run by Vanda Pharmaceuticals. The registered enrollment target is 25 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03291041, a Phase 2 study of Jet Lag Disorder, has completed, sponsored by Vanda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 3
- Study locations
Study Summary
A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag Disorder
Primary Outcome
Measured using polysomnography (PSG) and analyzed as change from baseline. Examination of the observational phase baseline data demonstrated that Night 3 was the night most disrupted.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tasimelteon
Study Locations (3)
California
- Vanda Investigational Site - Alameda
- Vanda Investigational Site - Santa Monica
Maryland
- Vanda Investigational Site - Chevy Chase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2016-07 |
| Est. Completion | 2017-11 |
| Phase | Phase 2 |
What the finished NCT03291041 record still lists
NCT03291041 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Jet Lag Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03291041 reports a single indexed study location in California, Maryland.
Frequently Asked Questions
What is clinical trial NCT03291041 about?
NCT03291041 is a clinical study titled "A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag Disorder". A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag Disorder
What is the current status of trial NCT03291041?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2016-07. Estimated completion is 2017-11.
What conditions does trial NCT03291041 study?
This clinical trial studies the following conditions: Jet Lag Disorder.
What interventions are being tested in trial NCT03291041?
The interventions under investigation include: Placebo (DRUG), Tasimelteon (DRUG).
Who is sponsoring clinical trial NCT03291041?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03291041 being conducted?
This trial has 3 study locations across California, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Jet Lag Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03291041's enrollment target sits among peer trials
25 1719th of 2000 higher than 245 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia